Overview FPT155 in Patients With Advanced Solid Tumors Status: Recruiting Trial end date: 2021-09-01 Target enrollment: Participant gender: Summary This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of FPT155 as monotherapy in patients with advanced solid tumors. Phase: Phase 1 Details Lead Sponsor: Five Prime Therapeutics, Inc.